Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Immunic
IMUX
$198M
| $112K | ﹤0.01% |
7,481
-50,259
| -87% | -$616K |
|
|
ARIS
3277
Aris Mining
ARIS
$3.25B
| $111K | ﹤0.01% |
33,634
| – | – |
|
3278
CareCloud
CCLD
$98.6M
| $111K | ﹤0.01% |
73,200
+12,600
| +21% | +$13.7K |
|
3279
Moleculin Biotech
MBRX
$2.72M
| $111K | ﹤0.01% |
346
+25
| +8% | +$5.19K |
|
|
MGRM
3280
DELISTED
Monogram Orthopaedics
MGRM
| $111K | ﹤0.01% |
+32,300
| New | +$97.4K |
|
3281
Alset
AEI
$48.2M
| $110K | ﹤0.01% |
106,366
+13,400
| +14% | +$15.5K |
|
|
BRNS
3282
Barinthus Biotherapeutics
BRNS
$23.1M
| $110K | ﹤0.01% |
29,699
+8,299
| +39% | +$28K |
|
|
DRRX
3283
DELISTED
DURECT Corp
DRRX
| $110K | ﹤0.01% |
186,166
-106,500
| -36% | -$152K |
|
3284
Pluri
PLUR
$19.5M
| $110K | ﹤0.01% |
23,800
+4,062
| +21% | +$18.1K |
|
3285
Paramount Gold Nevada
PZG
$119M
| $110K | ﹤0.01% |
294,500
+170,200
| +137% | +$57.4K |
|
|
ATXS
3286
DELISTED
Astria Therapeutics
ATXS
| $109K | ﹤0.01% |
14,200
+4,100
| +41% | +$22.7K |
|
|
TRVN
3287
DELISTED
Trevena, Inc.
TRVN
| $109K | ﹤0.01% |
6,062
-1,036
| -15% | -$15.5K |
|
3288
CEL-SCI Corp
CVM
$28.1M
| $108K | ﹤0.01% |
+1,323
| New | +$82.4K |
|
|
YARW
3289
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
| $108K | ﹤0.01% |
928
+408
| +78% | +$63.6K |
|
3290
Forte Biosciences
FBRX
$1.57B
| $107K | ﹤0.01% |
5,192
+116
| +2% | +$1.62K |
|
3291
Invivyd
IVVD
$194M
| $107K | ﹤0.01% |
27,200
-21,585
| -44% | -$40.8K |
|
3292
Q32 Bio
QTTB
$482M
| $106K | ﹤0.01% |
9,700
-300
| -3% | -$4.39K |
|
3293
Dominari Holdings
DOMH
$56.1M
| $105K | ﹤0.01% |
40,726
+1,400
| +4% | +$2.98K |
|
|
MHUA
3294
DELISTED
Meihua International Medical Technologies
MHUA
| $105K | ﹤0.01% |
+710
| New | +$130K |
|
3295
Scilex Holding
SCLX
$48.8M
| $105K | ﹤0.01% |
1,469
+1,083
| +281% | +$56.2K |
|
3296
MicroSectors FANG & Innovation -3x Inverse Leveraged ETN
BERZ
$15.5M
| $102K | ﹤0.01% |
130
-64
| -33% | -$72.7K |
|
|
VIRX
3297
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $102K | ﹤0.01% |
178,899
+30,700
| +21% | +$18.8K |
|
3298
Cyngn
CYN
$16M
| $100K | ﹤0.01% |
+46
| New | +$187K |
|
3299
SOPHiA GENETICS
SOPH
$561M
| $100K | ﹤0.01% |
21,300
+1,400
| +7% | +$5.24K |
|
3300
United States Antimony
UAMY
$920M
| $100K | ﹤0.01% |
400,358
+39,036
| +11% | +$11.7K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.